Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Addiction. 2017 Mar 13;112(8):1327–1328. doi: 10.1111/add.13794

The need for more nuance in headline adult cigarette smoking prevalence estimates

Sara C Hitchman 1,2, Jennifer L Pearson 3,4, Andrea C Villanti 3,4,5
PMCID: PMC5519138  NIHMSID: NIHMS876133  PMID: 28295768

Abstract

Recent changes in the tobacco and nicotine market make it more important than ever to have valid and reliable measures of tobacco and nicotine use that capture population exposure. Due to several factors that can affect smoking prevalence estimates, there is a need for surveillance measures to be harmonized, and for reporting and interpretation to be conducted carefully.

Keywords: Cigarette, measurement, prevalence, smoking, surveys, tobacco, United States


Recent changes in the tobacco and nicotine market make it more important than ever to have valid and reliable measures of tobacco and nicotine use that capture population exposure. New smoking prevalence estimates frequently make national headlines, and are used regularly to: (1) understand the consequences of tobacco and nicotine use on public health and (2) compare estimates across jurisdictions to understand how different tobacco control policies may be affecting smoking prevalence. Here, we call attention to some problems with existing smoking surveillance measures and methods, using the example of adult cigarette smoking prevalence in the United States.

Several factors can lead smoking prevalence estimates to be misinterpreted or distorted. First, non-cigarette combustible tobacco products such as small filtered cigars (that are often used like cigarettes), cigars, cigarillos, pipes and bidis are not always included in prevalence estimates. Many of these products have similar consequences for public health as cigarettes and should be included in smoking prevalence estimates. Moreover, they are often not subject to the same tobacco control measures as cigarettes (e.g. taxes, minimum pack size), and thus may be cheaper or more accessible than cigarettes. Secondly, the survey design underlying these estimates, including survey mode and sampling method, can affect who is included in samples, potentially under- or oversampling certain populations and yielding estimates that are higher or lower than the true values. Thirdly, national prevalence figures vary by the age used to define adulthood, with some surveys using 18+ and others using younger thresholds. Finally, the definition of a ‘smoker’ in headline rates can vary as well, such as past 30-day use, daily smoking or smoking every day/some days. Some definitions include additional conditions, such as a 100-cigarette life-time threshold which, combined with different thresholds for other tobacco and nicotine products in some cases (e.g. 50 times for cigar type products and one time for electronic cigarettes), further complicates interpretation [1,5]. The public health impact of smoking and the possible effects of policies or lack thereof may be misinterpreted if these factors are not considered.

The United States is one example of a country where adult cigarette smoking prevalence estimates are affected by some of these factors. Several surveys are used to measure tobacco use among US adults. We focus on the US National Health Interview Survey (NHIS) here because the US Centers for Disease Control (CDC) employs the NHIS to highlight smoking prevalence estimates in factsheets [2]. A recent New York Times article also highlighted that US adult cigarette smoking dropped to 15% in 2015 according to the NHIS [3].

This NHIS headline figure of 15.1%, which includes smoking cigarettes every day or some days and a 100-cigarette threshold, probably underestimates population exposure to combustible tobacco smoking in the United States [1]. The NHIS headline estimate excludes people using non-cigarette combustible tobacco products. Using annualized data from NHIS 2012–14, we find that the prevalence of non-cigarette combustible tobacco use, including products such as cigars, cigarillos and bidis among adults 18+, is 1.9%, with 0.8% using every day, 1.1% using some days and an additional 4.4% rarely using (rare use is an additional response option included for non-cigarette combustible products) [4]. If we consider young adults (aged 18–24 years), we see that the prevalence estimate is even higher at 2.7%, with 0.6% using every day, 2.1% some days and an additional 8.8% rarely using [4]. While it is possible that some proportion of non-cigarette combustible tobacco use is concurrent with cigarette smoking, it is likely that overall combustible tobacco use prevalence for adults 18+ in the United States is higher than 15.1%, and somewhere in line or just below the 2013–14 National Adult Tobacco Survey (NATS) estimate that 18.4% of US adults aged 18+ were current users of any combustible tobacco product (defined by NATS as use every day or some days, with different thresholds of life-time use by combustible tobacco product) [5].

Additionally, similar to other countries, US NHIS data highlight that cigarette smoking prevalence is higher in population subgroups, including sexual minorities (20.6%), those of low socio-economic status (i.e. below the poverty level, 26.1%) and those with serious psychological distress (40.6%) [1]. It is well documented that it has been increasingly difficult to recruit nationally representative survey samples in recent decades. Thus, it is possible that the US NHIS cigarette smoking prevalence estimate is low if members of groups who are difficult to engage in survey samples are under-represented.

Comparing across another data set, the NHIS cigarette smoking prevalence estimate (15.1%) is also lower than seen in cigarette (21.0%) smoking rates among people aged 18+ in the 2015 National Survey on Drug Use and Health (NSDUH) [6]. NSDUH’s primary measure of current cigarette use asks about past-month use rather than every day or some days as used in NHIS, and unlike the NHIS does not use the 100-cigarette threshold. The NHIS estimate is low even when compared to NSDUH’s prevalence estimate in people aged 12 years and older (19.4%). However, asking about past-month tobacco and nicotine product use, as conducted in the NSDUH, has been documented previously to overestimate regular use [7,8]. Nevertheless, this difference in cigarette smoking prevalence illustrates how different methods can affect national prevalence estimates, making them difficult to compare not only across jurisdiction, but even within countries.

The public health impact of combustible tobacco use in the United States is arguably distorted by headline cigarette smoking prevalence estimates because they often exclude non-cigarette combustible tobacco use, use imprecise definitions of current smoking and may be subject to other factors such as under-representation of difficult-to-engage groups. Cross-survey and cross-national comparisons of smoking prevalence estimates, including non-cigarette combustible products, are necessary to provide meaningful information to researchers, advocates and policy-makers. Rapid changes in the tobacco and nicotine market-place and policy environment highlight further the need for surveillance measures to be harmonized, and for reporting and interpretation to be conducted carefully.

Acknowledgments

S.C.H. is part of the UK Centre for Tobacco and Alcohol Studies, a UK Clinical Research Collaboration Public Health Research: Centre of Excellence and is funded by the Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council and the National Institute for Health Research under the auspices of the UK Clinical Research Collaboration (MR/K023195/1). A.C.V. was supported by in part by Truth Initiative, the Tobacco Centers of Regulatory Science (TCORS) award P50DA036114 from the National Institute on Drug Abuse and Food and Drug Administration (FDA) and the Centers of Biomedical Research Excellence P20GM103644 award from the National Institute on General Medical Sciences. J.L.P. is supported by Office of the Director of the National Institutes of Health, NIDA/NIH and FDA Center for Tobacco Products (CTP) under grant number K01DA037950. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration.

Footnotes

Declaration of interests

None.

References

RESOURCES